STOCK TITAN

Belite Bio: FDA moves tinlarebant action date to May 12

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Belite Bio (BLTE) said the FDA extended tinlarebant’s NDA review by three months, setting May 12, 2027, as the PDUFA action date. The FDA said the extension provides additional time to review information submitted in support of the application.

If no major deficiencies are identified during the ongoing review, the FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, by April 12, 2027. Tinlarebant is under review for Stargardt disease type 1.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointFDA extended tinlarebant NDA review by three months.
NDA review extension Three months FDA review of tinlarebant for Stargardt disease type 1
PDUFA action date May 12, 2027 Extended FDA review timeline for the tinlarebant NDA
Planned FDA communication date April 12, 2027 Conditional on no major deficiencies being identified; proposed labeling and any anticipated postmarketing requirement requests, if necessary
New Drug Application (NDA) regulatory
"New Drug Application (NDA) for tinlarebant"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
Prescription Drug User Fee Act (PDUFA) action date regulatory
"extended Prescription Drug User Fee Act (PDUFA) action date"
postmarketing requirement requests regulatory
"any anticipated postmarketing requirement requests"
bisretinoids medical
"accumulation of vitamin A-based toxins (known as bisretinoids)"
serum retinol binding protein 4 (RBP4) medical
"levels of serum retinol binding protein 4 (RBP4)"
Breakthrough Therapy Designation regulatory
"granted Breakthrough Therapy Designation"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the new FDA action date for Belite Bio (BLTE)’s tinlarebant NDA?

The new PDUFA action date is May 12, 2027, after the FDA extended its review by three months. The agency said the extension provides additional time to review information submitted in support of the NDA.

When does the FDA plan to communicate proposed labeling requests for Belite Bio (BLTE)’s tinlarebant NDA?

The FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, by April 12, 2027, if no major deficiencies are identified during its ongoing review.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-41359

 

Belite Bio, Inc

(Exact name of registrant as specified in its charter)

 

Not Applicable

(Translation of Registrant’s name into English)

 

12750 High Bluff Drive Suite 475,

San Diego, CA 92130

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ¨

 

 

 

 

 

On November 20, 2026, Belite Bio, Inc issued a press release entitled “Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA.” A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

This Report on Form 6-K and the related exhibit are incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933 and shall be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Exhibit No. Description of Exhibit
99.1 Press Release

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Belite Bio, Inc  
   
By: /s/ Yu-Hsin Lin  
Name: Yu-Hsin Lin  
Title: Chief Executive Officer and Chairman  

 

Date: November 20, 2026

 

 

 

 

Exhibit 99.1

 

 

 

Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA

 

SAN DIEGO, November 20, 2026 (GLOBE NEWSWIRE) - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that (i) it has extended the review period for the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1) by three months, with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027, and (ii) if no major deficiencies are identified during FDA’s ongoing review, the FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, with the Company by April 12, 2027.

 

The extension provides the FDA with additional time to review information provided in support of the NDA.  Belite Bio remains committed to working closely with the FDA throughout the review process, and is confident in the clinical evidence supporting tinlarebant and its potential to address the significant unmet medical need in the STGD1 patient population.

 

About Tinlarebant (a/k/a LBS-008)

 

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland, and Sakigake Designation in Japan for the treatment of STGD1.

 

About Belite Bio

 

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

 

 

 

 

Important Cautions Regarding Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to future expectations, plans and prospects, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding Belite Bio’s belief in the totality of evidence supporting tinlarebant and its ability to potentially bring tinlarebant as the first-ever approved treatment for STGD1, Belite Bio’s advancement of regulatory milestones and planned commercialization of its product candidates, FDA’s ongoing review of the NDA, the likelihood that the NDA will be approved and the timing of any approval decision, the tentative PDUFA date and anticipated date for the FDA to communicate proposed labeling requests and postmarketing requirement requests with the Company, as well as any other statements regarding matters that are not historical facts, and any other statements containing the words “may”, “will”, “expect”, “believe”, “target”, “plan”, “intend”, “continue”, “hope”, “potential”, “anticipate”, “estimate”, “remain”, “committed”, “confident”, “look forward”, and other similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors related to Belite Bio’s business, including but not limited to, Belite Bio’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; expectations for the timing of initiation, enrollment and completion of, and data relating to, its clinical trials; the timing to complete any ancillary clinical trials and/or to receive the interim/final data of such clinical trials; the timing to communicate with and submit trial data to regulatory authorities for drug approval in various jurisdictions; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio’s drug candidates; Belite Bio’s ability to successfully commercialize tinlarebant, if approved, including its ability to build out commercial infrastructure, achieve market acceptance, and execute a timely product launch; timing for Belite Bio to share additional data at upcoming medical meetings; the potential efficacy of tinlarebant to set a new benchmark for future research in inherited retinal disorders, as well as those risks more fully discussed in the “Risk Factors” section in Belite Bio’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

 

Media and Investor Relations Contact:

 

ir@belitebio.com

 

 

 

 

Filing Exhibits & Attachments

1 document

Keep reading